**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 90366

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Assessment of programmed death-ligand 1 expression in primary tumors and paired lymph node metastases of gastric adenocarcinoma**

Coimbra BC *et al*. PD-L1 in LNM of GC

Brendha Cação Coimbra, Marina Alessandra Pereira, Leonardo Cardili, Venancio Avancini Ferreira Alves, Evandro Sobroza de Mello, Ulysses Ribeiro Jr, Marcus Fernando Kodama Pertille Ramos

**Brendha Cação Coimbra, Marina Alessandra Pereira, Ulysses Ribeiro Jr, Marcus Fernando Kodama Pertille Ramos,** Department of Gastroenterology, Instituto do Cancer, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246000, Brazil

**Leonardo Cardili, Venancio Avancini Ferreira Alves, Evandro Sobroza de Mello,** Department of Pathology, Instituto do Cancer, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo 01246000, Brazil

**Author contributions:** Coimbra BC, Pereira MA, and Ramos MFKP contributed to the study design and data retrieval; Coimbra BC, Pereira MA, Alves VAF, Ribeiro Jr U, and Ramos MFKP were involved in the critical analysis;Coimbra BC and Pereira MA drafted the manuscript;Cardili L and Mello ES participated in the laboratory techniques and pathological analysis; Alves VAF and Ribeiro Jr U supervised the project; Alves VAF, Ribeiro Jr U, and Ramos MFKP reviewed the manuscript;Ramos MFKP implemented the research.

**Supported by** the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP agency), 2020/02880-1.

**Corresponding author: Marina Alessandra Pereira, MSc, PhD, Research Scientist,** Department of Gastroenterology, Instituto do Cancer, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Faculdade de Medicina, Universidade de São Paulo, Av Dr Arnaldo, 251, São Paulo 01246000, Brazil. marina.pereira@hc.fm.usp.br

**Received:** December 1, 2023

**Revised:** December 27, 2023

**Accepted:** January 31, 2024

**Published online:**

**Abstract**

BACKGROUND

Anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapy has demonstrated promising results on gastric cancer (GC). However, PD-L1 can express differently between metastatic sites and primary tumors (PT).

AIM

To compare PD-L1 status in PT and matched lymph node metastases (LNM) of GC patients and to determine the correlation between the PD-L1 status and clinicopathological characteristics.

METHODS

We retrospectively reviewed 284 GC patients who underwent D2-gastrectomy. PD-L1 was evaluated by immunohistochemistry (clone SP142) using the combined positive score. All PD-L1+ PT staged as pN+ were also tested for PD-L1 expression in their LNM. PD-L1(-) GC with pN+ served as the comparison group.

RESULTS

Among 284 GC patients included, 45 had PD-L1+ PT and 24 of them had pN+. For comparison, 44 PD-L1(-) cases with pN+ were included (sample loss of 4 cases).Of the PD-L1+ PT, 54.2% (13/24 cases) were also PD-L1+ in the LNM. Regarding PD-L1(-) PT, 9.1% (4/44) had PD-L1+ in the LNM. The agreement between PT and LNM had a kappa value of 0.483. Larger tumor size and moderate/severe peritumoral inflammatory response were associated with PD-L1 positivity in both sites. There was no statistical difference in overall survival for PT and LNM according to the PD-L1 status (*P* = 0.166 and *P* = 0.837, respectively).

CONCLUSION

Intra-patient heterogeneity in PD-L1 expression was observed between the PT and matched LNM. This disagreement in PD-L1 status may emphasize the importance of considering different tumor sites for analyses to select patients for immunotherapy.

**Key Words:** Gastric cancer; Lymph node; Programmed death ligand 1; Stomach neoplasms; Immunohistochemistry; Metastasis

Coimbra BC, Pereira MA, Cardili L, Alves VAF, Mello ES, Ribeiro Jr U, Ramos MFKP. Assessment of programmed death-ligand 1 expression in primary tumors and paired lymph node metastases of gastric adenocarcinoma. *World J Gastrointest Oncol* 2024; In press

**Core Tip:** This is a retrospective study comparing programmed death-ligand 1 (PD-L1) expression in primary tumors (PTs) and matched lymph node metastases (LNM) of gastric cancer patients who underwent D2-gastrectomy. Among 284 patients, 24 were PD-L1 positivity in PT and had LNM. Among patients with PD-L1 positive in PT, 54.2% were also positive for PD-L1 in LNM. Considering the PD-L1 negative patients in PT, 9.1% of had PD-L1 positive in LNM. Accordingly, the intra-patient heterogeneity in PD-L1 expression between the PT and matched LNM found in our study may emphasize the importance of considering the site of tumor sample examined when selecting patients for immunotherapy.

**INTRODUCTION**

Gastric cancer (GC) is a globally distributed disease, ranking worldwide as the fifth most common cause of cancer and fourth in mortality[1]. Surgery remains the main treatment modality, and the addition of perioperative or adjuvant chemotherapy improves the survival of advanced resected cases[2]. Different conventional chemotherapy combination schemes have been used according to the patient’s tolerance and availability of drugs[3].

Recently, immunotherapy with checkpoint inhibition through the blockade of the programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) has emerged as a promising modality in several tumors, including GC[4,5]. The PD-1/PD-L1 pathway is a key in the negative regulation of cell-mediated immune responses. Anti-PD-1/PD-L1 antibodies prevent inhibitory effects of the PD-1/PD-L1 pathway and enhance T cell function, demonstrating robust antitumor responses[5-7].

PD-L1 expression, assessed with immunohistochemistry, has been used as marker to predict the therapeutic effect of anti-PD-1 or anti-PD-L1 immunotherapy in GC, as well as patients’ prognosis[8-10]. However, GC is a highly heterogeneous disease from the morphological and molecular standpoints[11], with both intra-tumoral and intra-patient [between the primary tumor (PT) and its metastatic sites] variability[11-14]. Recent clinical studies reported that although patients with PD-L1+ tumors demonstrate higher rates of response to anti-PD-1/PD-L1 immunotherapy, those with PD-L1(-) tumors may also benefit from anti-PD-1/PD-L1 immunotherapy[4,7,15-17].

Indeed, the evaluation of PD-L1 is mostly based on PTs. However, immune checkpoints may express differently between primary and metastatic tumors, and this difference may have an impact on the selection of patients for therapy[13,18,19]. Thus, this study aimed to compare PD-L1 expression in PTs and its respective lymph node metastases (LNM) in patients with GC and to determine the association between PD-L1 status and clinicopathologic characteristics.

**MATERIALS AND METHODS**

***Patients***

We performed a retrospective review of all patients with GC who underwent gastrectomy with curative intent at a reference Cancer Center between 2009 and 2016, from a prospective collected medical database. Inclusion criteria were: (1) Gastric adenocarcinoma; (2) D2 lymphadenectomy; (3) R0 resection; and (4) Formalin-fixed paraffin-embedded tissue blocks available for analysis. Patients with remnant GC, palliative resections, and systemic metastatic disease were excluded.

Clinical data included sex, age, body max index (BMI) (kg/cm²), hemoglobin (g/dL), neutrophil-lymphocyte ratio (NLR), American Society of Anesthesiologists Classification, and Charlson-Deyo Comorbidity Index (CCI) excluding cancer as a comorbidity.

All patients underwent total or subtotal gastrectomy with D2 lymph node dissection based on the guidelines of the Japanese Gastric Cancer Association and Brazilian Gastric Cancer Association guidelines[2,20]. The tumor stage was defined according to the 8th edition of the TNM, as proposed by the International Union Against Cancer[21]. Surgical specimens were evaluated by histopathological criteria according to the College of American Pathologists protocol[22]. Postoperative follow-up appointments were performed once every three months in the first year and every 6 months in the following years. Physical examination and laboratory tests were performed on patient reassessments. Imaging and upper gastrointestinal endoscopy were selectively performed. Loss of follow-up was characterized as consecutively missed medical appointments for more than 12 months.

***Sample selection and pathological analysis***

First, PD-L1 expression was assessed in all PTs. After that, we selected all PD-L1+ patients in the PT site (PD-L1+ PT) who had LNMs (pN+). Patients with PD-L1(-) negative in the PT [PD-L1(-) PT] and pN+ were selected as the comparison group in the proportion of 1:2. The LNM from both groups were also evaluated for PD-L1 status by immunohistochemical (IHC) staining. Inclusion of PD-L1(-) PT cases was performed chronologically and sequentially.

Hematoxylin and eosin-stained slides were reviewed by a pathologist to select representative tumor areas from PT and LNM. The most representative LNM from each patient was selected for analysis, and the entire section was subjected to IHC staining. The lymph nodes evaluated were all regional lymph nodes, located in the greater or lesser gastric curvature.

The PT was evaluated through the tissue microarray construction (TMA) construction, using a precision mechanized system (Beecher Instruments, Silver Springs, MD, United States), with three tumor tissue cores from each patient. The TMA blocks were cut into 4 μm sections and submitted to IHC staining.

For IHC analysis of PD-L1 expression, sections were dewaxed, rehydrated, and submitted to heat-induced antigen retrieval using a citrate buffer. Endogenous peroxidase was blocked, and slides were incubated with primary antibody anti-PD-L1 (clone SP142) overnight at 4 ˚C. Avidin-biotin-free short polymer-based peroxidase (Novolink Polymer Detection System, Novocastra, Newcastle, United Kingdom) was used for amplification. Reaction products were visualized with diaminobenzidine, and sections were counterstained with Harris’s Hematoxylin. Microscopic analysis was carried out by conventional light microscopy.

PD-L1 expression was evaluated in PT and LNM using the combined positive score (CPS)[23], which is defined based on the number of tumor cells and immune cells staining for PD-L1, divided by the total number of viable tumor cells, multiplied by 100. CPS ≥ 1 was defined as PD-L1+.

***Statistical analysis***

The *χ2* test or Fisher test (for nominal variables) and *t*-test or Mann-Whitney *U* (for continuous variables) was performed to assess the association of clinicopathological parameters with PD-L1 status. The analysis of the concordance between PD-L1 status in PT and LNM was performed using the Kappa coefficient. The Kappa coefficient was interpreted according to the Landis and Koch criteria, classified as poor (< 1%), slight (1%-20%), fair (21%-40%), moderate (41%-60%), substantial (61%-80%), almost perfect (81%-100%). Disease-free survival (DFS) was calculated from the date of surgery to the date of relapse or death. Overall survival (OS) was defined as the time between surgery and death of any cause. DFS and OS were estimated using the Kaplan-Meier method, and differences in survival were compared using the Log-Rank test. Statistical analyses were performed using the Statistical software package SPSS for Windows, version 20.0 (SPSS Inc., Chicago, IL). Statistical significance was defined as *P* < 0.05.

**RESULTS**

During the selected period, 284 patients were eligible for the study. Among them, 45 (15.8%) patients were positive for PD-L1 in the PT. Of these, 24 had lymph node metastasis (pN+) and were included for evaluation (PD-L1+ PT group). Among the remaining 239 patients with PD-L1(-) in the PT, 48 with pN+ were selected for comparison. Sample loss occurred in 4 cases, and the final control group was composed of 44 patients with PD-L1(-) PT. Microscopic findings of PT and LNM are showed in Figure 1.

In the PD-L1+ PT group, 54.2% (13/24 cases) were also PD-L1+ in the LNM. Regarding patients with PD-L1(-) PT, 9.1% (4/44) had PD-L1+ LNM (Table 1). The agreement between PT and LNM had a kappa value of 0.483. As for PD-L1 expression in LNM, most cases showed weak to moderate expression intensity, with a predominance of expression in both immune and tumor cells (15 cases). Only two patients exhibited PD-L1+ exclusively in immune cells in the LNM.

***Clinical******characteristics of GC according to PD-L1 expression in PT and LNM***

Comparing groups according to PD-L1 status, there were no differences regarding sex, age, BMI, NLR, and CCI between both groups from PT and LNM. Seric hemoglobin levels were lower in patients with PD-L1+ PT. The clinical and surgical characteristics of the PD-L1(-) and PD-L1+ groups for PT and LNM are summarized in Table 2.

***Pathological characteristics of GC according to PD-L1 expression in PT and LNM***

PD-L1+ groups in both PT and LNM were significantly associated with larger lesions and moderate/severe peritumoral inflammatory response (Table 3). PD-L1+ PT was associated with venous invasion (*P* = 0.017) and PD-L1+ LNM with a higher number of retrieved lymph node (*P* = 0.035). There were no differences between PD-L1+ and PD-L1(-) groups regarding the grade of histological differentiation, pT, and pTNM. Pathological characteristics are summarized in Table 3.

***Postoperative and follow-up***

The mean length of hospital stay was 11 d (SD = 8.6, range 4-45 d). A total of 41 patients received some preoperative or postoperative chemotherapy treatment, but none of them received immunotherapy. After a median follow-up of 39.2 months, 30 patients had a recurrence and 37 died. Estimated DFS and OS for the entire study population were 68.4% and 55.6%, respectively.

Regarding the PT, there was no statistical difference in DFS rate according to PD-L1(-) and PD-L1+ status (37.9% *vs* 48%, respectively; *P* = 0.336); and for OS rate (37.5% *vs* 52.2%, respectively; *P* = 0.166). Considering the LNM, the median DFS was 26.4 and 26.3 months for PD-L1+ and PD-L1 negative cases (*P* = 0.995). No difference was observed for OS between PD-L1+ and negative groups (*P* = 0.837). The median OS was 33.3 months and 38.5 months for PD-L1(-) and PD-L1+ in LNM, respectively.

**DISCUSSION**

In the present study, we found a moderate concordance of PD-L1 expression between PT and paired LNM in patients with GC. As PD-L1 testing is currently aimed at selecting patients for immunotherapy, LNM assessment has the potential to increase the number of candidates by 10%. Further, PD-L1+ in both PT and LNM were associated with larger tumor size and moderate/severe peritumoral inflammatory response.

Although immunotherapy has emerged as a breakthrough in several malignancies, clinical indication of anti-PD-1/PD-L1 is limited to a small subset of patients, including patients with GC[7]. Food and Drug Administration (FDA) recently extended approval of pembrolizumab treatment for patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient (dMMR) solid tumors that progressed despite prior treatment[24]. Tumors expressing PD-L1 CPS ≥ 1 as determined by an FDA-approved test, exhibiting disease progression or after two or more therapeutic attempts were also included in recent approval[4].

As PD-L1 staining has proven to be decisive for immunotherapy indication, the expression of PD-L1 has started to be widely investigated in different types of tumor and sites. Recent studies have emphasized the heterogeneity of PD-L1 expression in tumor samples, showing a significantly higher accuracy of resection samples when compared to isolated biopsies[25,26]. Similarly, we also observed heterogeneity when correlating expression from different sites (PT *vs* metastatic site), showing that not only tumor samples - but also the site of evaluation - can have differences in expression.

This correlation of PD-L1 expression has been previously evaluated in other tumors[27-30]. A recent systematic review and meta-analysis extensively summarized the discordant status between PT and distant metastasis for nine different cancer types including non-small cell lung cancer, breast cancer, colorectal cancer (CRC), kidney renal clear cell carcinoma, head and neck squamous cell carcinoma, bladder cancer, melanoma, synovial sarcoma, and cervical cancer[27]. It was reported a pooled discordance rate for PD-L1 of 22% when comparing sites. Moreover, the PD-L1 conversion rate from PT to the metastatic site was 41% from positive to negative, whereas that from negative to positive was 16%, encouraging an evaluation of both PT and metastatic sites for better treatment eligibility[27].

In fact, the results regarding PD-L1 when evaluated in PT and metastasis, present variable results in the studies. An overall similar prevalence in PD-L1 expression between PT and LNM has been reported in CRC. The PD-L1 overexpression was more common along with a higher tumor mutational burden (TMB). Interestingly, a TMB-high status was significantly more frequent in lymph node than in PT and distant sites[29]. Differences between MMR status have also been previously described. MSI and MMR are also pivotal in immunotherapy eligibility since anti-PD-L1 therapy has shown benefits for patients with dMMR or MSI-H tumors[24,31]. A previous study found a high concordance rate between primary CRCs and matched metastatic lesions, describing some changes from MSI-H in primary CRC to MSS when peritoneal and ovarian metastases, suggesting the need for a new biopsy to evaluate MSI-H/dMMR status when an anti-PD-1 therapy is planned[32].

A good agreement of PD-L1 expression between the PT and LNM (90.9%) was reported in patients with esophageal cancer who previously received neoadjuvant chemotherapy. Among the 35 patients with PT PD-L1(-), 3 had positive expression in the LNM, contributing to the possibility of positivity amongst patients with negative PT site[33].

Some authors suggest that microenvironment characteristics may contribute to the differences in expression between PT and LNM, such as infiltration of cytotoxic T lymphocytes were considered to play a pivotal role in higher PD-L1 positivity by tumor positive score status found in metastatic sites[28].

In a study that evaluated the expression of PD-L1 in paired sample of 47 breast tumor and axillary LNM samples, PT and matched lymph node showed a positive PD-L1 rate of 29.8% (14/47) and 14.8% (7/47), respectively. When comparing matched sites, amongst the 14 patients with positive PD-L1(-) PT, 50 were also positive in the paired LNM. All 33 patients with PD-L1(-) PT showed negative PD-L1 expression in paired LNM[30]. Similarly, another study showed high fidelity across the matched primary and metastatic samples from treatment-naive patients, as 94% (16/17) of cases showed concordant staining between the PT and metastatic tumor. However, as for tumor-associated inflammatory cells, a gain of PD-L1 immune stromal positivity was observed in the site of metastasis in five cases (4 nodal and 1 lung metastasis)[34].

In GC, data regarding the concordance rate between PD-L1 in primary GC and matched regional LNM are limited. Gao *et al*[35] demonstrated a higher PD-L1 expression rate in LNM than in PT (45.4% *vs* 38.7%, *P* = 0.005). Also, similar to our findings, PD-L1 expression was inconsistent in PT and LNM from the same patient. This suggests that, when evaluated only one site exclusively, false-negative results may contribute to the inaccuracy of using PD-L1 as a predictor of response to anti-PD-1/PD-L1 immunotherapy[35].

Differences have also been reported in relation to PD-L1 positivity in tumor cells and tumor-infiltrating immune cells (TIC) between PT and a subset of paired LNM. Svensson *et al*[9] demonstrated that PD-L1 expression TIC was significantly higher in LNM compared to PT (54.4% *vs* 41.2%)[9]. In our study, PD-L1 expression was evaluated using the CPS. Therefore, we did not examine this difference in relation to the positivity pattern separately.

Interestingly, in addition to the heterogeneity of expression, some findings observed when evaluating PD-L1 expression in distant metastases beyond the PT and LNM suggest that tumor cells acquire PD-L1 expression during disease progression. Liu *et al*[14] showed up to 33% discordance of PD-L1 CPS between primary GC and LNM and/or distant metastasis, and the proportion of PD-L1 positive tumor cells increased from primary GC (26%) to LNM (42%) and was highest in distant metastasis (75%).

In a study that compared PD-L1 expression in paired baseline primary and baseline metastatic tumors from 62 patients with gastroesophageal adenocarcinoma, a spatial heterogeneity was noted in PT, which were PD-L1 positive, but frequently PD-L1 negative in paired metastases[13]. They found that 36 PT were PD-L1+, compared with 18 metastatic tumors. Baseline paired primary and metastatic tumor PD-L1-status were 61% concordant (38/62). Among the 26 PD-L1(-) in PT, 23 (88%) remained PD-L1(-) in the metastatic tumor. In contrast, of 36 PD-L1+ PT, only 15 (42%) remained PD-L1+ in the metastatic tumor[13]. In our study, the overall agreement rate was 77.9% (53/68). Conversely, the disagreement was 22.1% (15/68). Of the 24 PD-L1+ PTs, only 13 (54%) were positive on paired LNM. While in the 44 PD-L1(-) cases in PT, 9 were PD-L1+ in LNM (9.1%).

Thus, as the benefit of targeted therapies is limited to a restricted group of patients, improve assessment of PD-L1 expression may be important to broaden the therapeutic indication and evaluate the results obtained with the treatment in clinical trials. The PD-L1 positivity seen at the metastatic site could explain the survival benefit seen in some PT PD-L1(-) patients who received immunotherapy in clinical trials[4,17]. At the same time, since PD-L1 status in PT did not show a clear dependence on metastatic site, these results may also provide explanation for lack of benefit of immune checkpoint inhibitor therapy in some metastatic patients, despite positive PD-L1 scoring in PT. Thus, evaluation of intra-patient heterogeneity of PD-L1 expression may better predict which patients are most likely to benefit from therapy.

The present study has limitations. The included sample size is relatively small, which limits the assessment of survival outcomes and clinical characteristics associated with PD-L1 status for both sites. We evaluated PD-L1 expression in the PTs and a single lymph node for each patient as a first assessment, limited by sample availability and feasibility. Furthermore, despite suggesting a potential increase in the patient that could benefit from immunotherapy by evaluating PD-L1 beyond the PT site, we cannot determine whether there will actually be a survival improvement in these cases, as our patients were not treated with immunotherapy with anti-PD-1/PD-L1.

On the other hand, to our knowledge, this study is the first to address the intra-patient heterogeneity of PD-L1 expression in paired PT and LNM in western patients with GC who underwent a curative intent gastrectomy. Our study demonstrated that PD-L1 positivity rate was varied between PT and LNM, and the agreement across tumor sites is not necessarily the same. Accordingly, as in our cohort of patients without PD-L1 expression in the PT were positive in LNM in 9.1% of the cases, we suggested that biopsies of primary GC and metastatic sites should be tested before considering treatment options. In our study, lymph node testing could increase the number of potential candidates for immunotherapy based on PD-L1 expression, which may be important to expand the immune checkpoint inhibitor therapy indication.

**CONCLUSION**

Intra-patient heterogeneity of PD-L1 expression were observed between the primary GC and matched LNM. The heterogeneity in PD-L1 status may emphasize the importance of considering the site of tumor sample examined when selecting patients for immunotherapy, since it could influence the role of PD-L1 as a predictive biomarker for response to immune checkpoint inhibitors.

**ARTICLE HIGHLIGHTS**

***Research background***

Programmed death ligand 1 (PD-L1) expression is a potential biomarker for response to immune checkpoint inhibitors in some tumors, including in gastric cancer (GC). However, many biomarkers exhibit heterogeneity in GC, and intra-patient heterogeneity of PD-L1 expression may influence its role as predictive biomarkers.

***Research motivation***

Data regarding the concordance rate between PD-L1 in primary GC and matched regional lymph node metastasis (LNM) are limited.

***Research objectives***

This study aimed to compare PD-L1 expression in paired primary tumor (PT) and LNM from patients with GC. Clinicopathological characteristics and prognosis according to PD-L1 status were also evaluated.

***Research methods***

We retrospectively reviewed 284 GC patients who underwent D2-gastrectomy. PD-L1 was evaluated by immunohistochemistry (clone SP142). PD-L1 status was defined as positive using the combined positive score ≥ 1. PD-L1+ in PT staged as pN+ were also tested for PD-L1 expression in their LNM. PD-L1(-) GC with pN+ served as the comparison group.

***Research results***

Among 284 patients, 24 were PD-L1 positivity in PT and had LNM. PD-L1+ in both PT and LNM were associated with larger tumor size and moderate/severe peritumoral inflammatory response. Among patients with PD-L1 positive in PT, 54.2% were also positive for PD-L1 in LNM. Considering the PD-L1 negative patients in PT, 9.1% of had PD-L1 positivity in LNM. The agreement between PT and LNM had a kappa value of 0.483 (moderate concordance). There was no difference in overall survival for PT and LNM according to the PD-L1 status.

***Research conclusions***

Our findings demonstrated that the expression of PD-L1 in the PT and LNM of patients with GC demonstrated discordance, and the heterogeneity observed between the sites evaluated may impact the use of PD-L1 as predictive biomarkers of response to immune checkpoint inhibitors.

***Research perspectives***

The intra-patient heterogeneity in PD-L1 status may emphasize the importance of considering the site of tumor sample examined when selecting patients for immunotherapy, and this difference in PD-L1 status between PT and matched LNM may be evaluated in future trials to justify the response observed in some PD-L1 negative cases in PT.

**REFERENCES**

1 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

2 **Japanese Gastric Cancer Association**. Japanese gastric cancer treatment guidelines 2018 (5th edition). *Gastric Cancer* 2021; **24**: 1-21 [PMID: 32060757 DOI: 10.1007/s10120-020-01042-y]

3 **Lordick F**, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2022; **33**: 1005-1020 [PMID: 35914639 DOI: 10.1016/j.annonc.2022.07.004]

4 **Fashoyin-Aje L**, Donoghue M, Chen H, He K, Veeraraghavan J, Goldberg KB, Keegan P, McKee AE, Pazdur R. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. *Oncologist* 2019; **24**: 103-109 [PMID: 30120163 DOI: 10.1634/theoncologist.2018-0221]

5 **Muro K**, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. *Lancet Oncol* 2016; **17**: 717-726 [PMID: 27157491 DOI: 10.1016/S1470-2045(16)00175-3]

6 **Bilgin B**, Sendur MA, Bülent Akıncı M, Şener Dede D, Yalçın B. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. *Curr Med Res Opin* 2017; **33**: 749-759 [PMID: 28055269 DOI: 10.1080/03007995.2017.1279132]

7 **Pardoll DM**. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012; **12**: 252-264 [PMID: 22437870 DOI: 10.1038/nrc3239]

8 **Tabernero J**, Cutsem EV, Bang YJ, Fuchs CS, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Salguero HRC, Mansoor W, Braghiroli MIFM, Goekkurt E, Chao J, Wainberg ZA, Kher U, Shah S, Kang SP, Shitara K. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. *J Clin Oncol* 2019; **37** [DOI: 10.1200/JCO.2019.37.18\_suppl.LBA4007]

9 **Svensson MC**, Borg D, Zhang C, Hedner C, Nodin B, Uhlén M, Mardinoglu A, Leandersson K, Jirström K. Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. *Front Oncol* 2019; **9**: 136 [PMID: 30931254 DOI: 10.3389/fonc.2019.00136]

10 **Pereira MA**, Ramos MFKP, Faraj SF, Dias AR, Yagi OK, Zilberstein B, Cecconello I, Alves VAF, de Mello ES, Ribeiro U Jr. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. *J Surg Oncol* 2018; **117**: 829-839 [PMID: 29534305 DOI: 10.1002/jso.25022]

11 **Cancer Genome Atlas Research Network**. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; **513**: 202-209 [PMID: 25079317 DOI: 10.1038/nature13480]

12 **Kim HS**, Shin SJ, Beom SH, Jung M, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY, Kim H. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. *Oncotarget* 2016; **7**: 44608-44620 [PMID: 27331626 DOI: 10.18632/oncotarget.10115]

13 **Zhou KI**, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, Tan C, Wang Y, Catenacci DVT. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. *Clin Cancer Res* 2020; **26**: 6453-6463 [PMID: 32820017 DOI: 10.1158/1078-0432.CCR-20-2085]

14 **Liu DHW**, Grabsch HI, Gloor B, Langer R, Dislich B. Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases. *J Cancer Res Clin Oncol* 2023; **149**: 13345-13352 [PMID: 37491637 DOI: 10.1007/s00432-023-05142-x]

15 **Fuchs CS**, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. *JAMA Oncol* 2018; **4**: e180013 [PMID: 29543932 DOI: 10.1001/jamaoncol.2018.0013]

16 **Kawazoe A**, Yamaguchi K, Yasui H, Negoro Y, Azuma M, Amagai K, Hara H, Baba H, Tsuda M, Hosaka H, Kawakami H, Oshima T, Omuro Y, Machida N, Esaki T, Yoshida K, Nishina T, Komatsu Y, Han SR, Shiratori S, Shitara K. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. *Eur J Cancer* 2020; **129**: 97-106 [PMID: 32145474 DOI: 10.1016/j.ejca.2020.02.002]

17 **Tabernero J**, Cutsem EV, Bang Y, Fuchs C, Wyrwicz L, Lee K, Kudaba I, Garrido M, Chung H, Castro Salguero H, Mansoor W, Braghiroli M, Goekkurt E, Chao J, Wainberg Z, Kher U, Shah S, Kang S, Shitara K. Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. *Ann Oncol* 2019; **30**: IV152-IV153 [DOI: 10.1093/annonc/mdz183.001]

18 **Son SM**, Woo CG, Kim DH, Yun HY, Kim H, Kim HK, Yang Y, Kwon J, Kwon M, Kim TY, Kim HD, Koh JY, Park SH, Shin EC, Han HS. Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients. *Sci Rep* 2020; **10**: 14293 [PMID: 32868848 DOI: 10.1038/s41598-020-71340-z]

19 **Erdogdu IH**. MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers. *Gastroenterol Res Pract* 2019; **2019**: 4785098 [PMID: 30881447 DOI: 10.1155/2019/4785098]

20 **Barchi LC**, Ramos MFKP, Dias AR, Andreollo NA, Weston AC, LourenÇo LG, Malheiros CA, Kassab P, Zilberstein B, Ferraz ÁAB, Charruf AZ, Brandalise A, Silva AMD, Alves B, Marins CAM, Leite CV, Bresciani CJC, Szor D, Mucerino DR; Consensus. II Brazilian Consensus on Gastric Cancer By The Brazilian Gastric Cancer Association. *Arq Bras Cir Dig* 2020; **33**: e1514 [PMID: 32844884 DOI: 10.1590/0102-672020190001e1514]

21 **Amin MB**, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR. AJCC Cancer Staging Manual (8th edition). United States: Springer International Publishing, 2017

22 **Shi C**, Berlin J, Branton PA, Fitzgibbons PL, Frankel WL, Hofstetter WL, Kakar S, Kelsen D, Klepeis V, Lewis JT, Tan LH, Washington MK. Protocol for the Examination of Specimens From Patients With Carcinoma of the Stomach. *College of American Pathologists* 2020

23 **Pereira MA**, Ramos MFKP, Dias AR, Ribeiro R, Cardili L, Zilberstein B, Cecconello I, Ribeiro U Jr, de Mello ES, de Castria TB. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. *Virchows Arch* 2021; **478**: 1039-1048 [PMID: 33098489 DOI: 10.1007/s00428-020-02956-9]

24 **Marcus L**, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. *Clin Cancer Res* 2019; **25**: 3753-3758 [PMID: 30787022 DOI: 10.1158/1078-0432.CCR-18-4070]

25 **Schoemig-Markiefka B**, Eschbach J, Scheel AH, Pamuk A, Rueschoff J, Zander T, Buettner R, Schroeder W, Bruns CJ, Loeser H, Alakus H, Quaas A. Optimized PD-L1 scoring of gastric cancer. *Gastric Cancer* 2021; **24**: 1115-1122 [PMID: 33954872 DOI: 10.1007/s10120-021-01195-4]

26 **Halske C**. [Intratumoral heterogeneity of gastric cancer-impact on biomarker evaluation]. *Pathologe* 2020; **41**: 76-82 [PMID: 33427920 DOI: 10.1007/s00292-020-00881-x]

27 **Zou Y**, Hu X, Zheng S, Yang A, Li X, Tang H, Kong Y, Xie X. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis. *EBioMedicine* 2021; **63**: 103137 [PMID: 33310681 DOI: 10.1016/j.ebiom.2020.103137]

28 **Yamada T**, Miki Y, Suzuki M, Kondoh O, Saito-Koyama R, Ono K, Okada Y, Sasano H. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma. *Cancer Med* 2022; **11**: 479-491 [PMID: 34907653 DOI: 10.1002/cam4.4444]

29 **Puccini A**, Seeber A, Xiu J, Goldberg RM, Soldato D, Grothey A, Shields AF, Salem ME, Battaglin F, Berger MD, El-Deiry WS, Tokunaga R, Naseem M, Zhang W, Arora SP, Khushman MM, Hall MJ, Philip PA, Marshall JL, Korn WM, Lenz HJ. Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. *NPJ Precis Oncol* 2021; **5**: 95 [PMID: 34707195 DOI: 10.1038/s41698-021-00230-y]

30 **Yuan C**, Liu Z, Yu Q, Wang X, Bian M, Yu Z, Yu J. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. *Sci Rep* 2019; **9**: 14356 [PMID: 31591439 DOI: 10.1038/s41598-019-50898-3]

31 **Le DT**, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med* 2015; **372**: 2509-2520 [PMID: 26028255 DOI: 10.1056/NEJMoa1500596]

32 **He WZ**, Hu WM, Wang F, Rong YM, Yang L, Xie QK, Yang YZ, Jiang C, Qiu HJ, Lu JB, Zhang B, Ding PR, Xia XJ, Shao JY, Xia LP. Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer. *J Natl Compr Canc Netw* 2019; **17**: 1174-1183 [PMID: 31590148 DOI: 10.6004/jnccn.2019.7308]

33 **Konno-Kumagai T**, Fujishima F, Nakamura Y, Nakano T, Nagai T, Kamei T, Sasano H. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients. *Dis Esophagus* 2019; **32** [PMID: 30085020 DOI: 10.1093/dote/doy063]

34 **Dill EA**, Gru AA, Atkins KA, Friedman LA, Moore ME, Bullock TN, Cross JV, Dillon PM, Mills AM. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors. *Am J Surg Pathol* 2017; **41**: 334-342 [PMID: 28195880 DOI: 10.1097/PAS.0000000000000780]

35 **Gao Y**, Li S, Xu D, Chen S, Cai Y, Jiang W, Zhang X, Sun J, Wang K, Chang B, Wang F, Hong M. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. *Chin J Cancer* 2017; **36**: 61 [PMID: 28754154 DOI: 10.1186/s40880-017-0226-3]

**Footnotes**

**Institutional review board statement:** The study was approved by the hospital ethics committee and registered online (https://plataformabrasil.saude.gov.br; CAAE: 26380019.6.0000.0065).

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 1, 2023

**First decision:** December 17, 2023

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Lai SW, Taiwan; Stan FG, Romania; Wang ZX, China **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 Microscopic findings of primary tumor and metastatic lymph nodes in cases with gastric adenocarcinoma.** A: Gastric adenocarcinoma with positive staining for programmed death-ligand 1 (PD-L1), original magnification, 20 ×; B: Gastric adenocarcinoma PD-L1 negative, original magnification, 20 ×; C: Lymph node with adenocarcinoma metastasis stained with hematoxylin eosin (HE), original magnification, 10 ×; D: Positive PD-L1 staining in the metastatic lymph node showed in “C”, from a case with PD-L1 negative in gastric tumor, original magnification, 10 ×; E: Lymph node metastasis in HE staining, original magnification, 10 ×; F: Positive staining for PD-L1 in the same lymph node, from a case with primary tumor also positive for PD-L1, original magnification, 20 ×.

**Table 1 Programmed death-ligand 1 expression in primary tumor site and metastatic lymph node**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Primary tumor** | **Total** | **PD-L1 negative** | **PD-L1 positive** | ***P* value** |
| ***n* = 68 (%)** | ***n* = 44 (%)** | ***n* = 24 (%)** |
| **Lymph node** |  |  |  | < 0.001 |
| PD-L1 negative | 51 (75) | 40 (90.9) | 11 (45.8) |  |
| PD-L1 positive | 17 (25) | 4 (9.1) | 13 (54.2) |  |
| **Total (%)** | 100.0 | 64.7 | 35.3 |  |

PD-L1: Programmed death-ligand 1.

**Table 2 Clinical characteristics according to the positivity for programmed death-ligand 1 in the primary tumor and lymph node metastasis**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **Primary tumor** | | ***P* value** | **Lymph node** | | ***P* value** |
| **PD-L1(-), *n* = 44 (%)** | **PD-L1+, *n* = 24 (%)** | **PD-L1(-), *n* = 51 (%)** | **PD-L1+, *n* = 17 (%)** |
| **Sex** |  |  | 0.417 |  |  | 0.558 |
| Female | 14 (31.8) | 10 (41.7) |  | 19 (37.3) | 5 (29.4) |  |
| Male | 30 (68.2) | 14 (59.3) |  | 32 (62.7) | 12 (70.6) |  |
| **Age (yr)** |  |  | 0.721 |  |  | 0.127 |
| mean (SD) | 60.7 (11.8) | 61.7 (12.3) |  | 59.8 (12.4) | 64.9 (9.7) |  |
| **BMI (kg/cm²)** |  |  | 0.717 |  |  | 0.271 |
| mean (SD) | 24.3 (5.6) | 23.9 (3.9) |  | 24.6 (5.2) | 23.0 (4.5) |  |
| **Hemoglobin (g/dL)** |  |  | 0.008a |  |  | 0.148 |
| mean (SD) | 12.4 (2.1) | 10.8 (2.5) |  | 12.1 (2.2) | 11.1 (2.7) |  |
| **Neutrophil-lymphocyte ratio** | |  | 0.703 |  |  | 0.879 |
| mean (SD) | 3.30 (4.43) | 3.72 (4.21) |  | 3.39 (4.69) | 3.31 (3.08) |  |
| **CCI** | |  | 0.974 |  |  | 0.539 |
| CCI 0 | 31 (70.5) | 17 (70.8) |  | 35 (68.6) | 13 (76.5) |  |
| CCI ≥ 1 | 13 (29.5) | 7 (29.2) |  | 16 (31.4) | 4 (23.5) |  |
| **Tumor site** |  |  | 0.635 |  |  | 0.317 |
| Lower | 25 (56.8) | 15 (62.5) |  | 32 (62.7) | 8 (47.1) |  |
| Middle | 12 (27.3) | 6 (25) |  | 11 (21.6) | 7 (41.2) |  |
| Upper | 4 (9.1) | 3 (12.5) |  | 5 (9.8) | 2 (11.8) |  |
| All | 3 (6.8) | 0 (0) |  | 3 (5.9) | 0 (0) |  |
| **Type of resection** |  |  | 0.323 |  |  | 0.122 |
| Subtotal | 22 (50) | 9 (37.5) |  | 26 (51) | 5 (29.4) |  |
| Total | 22 (50) | 15 (62.5) |  | 25 (49) | 12 (70.6) |  |

a*P* < 0.05.

PD-L1: Programmed death-ligand 1; BMI: Body mass index; CCI: Charlson-Deyo Comorbidity Index.

**Table 3 Pathological characteristics according to the positivity for programmed death-ligand 1 in the primary tumor and lymph node metastasis**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **Primary tumor** | | ***P* value** | **Lymph node** | | ***P* value** |
| **PD-L1(-), *n* = 44 (%)** | **PD-L1+, *n* = 24 (%)** | **PD-L1(-), *n* = 51 (%)** | **PD-L1+, *n* = 17 (%)** |
| **Tumor size (cm)** |  |  | **0.011** |  |  | **0.005** |
| mean (SD) | 5.8 (3.3) | 8.1 (3.6) |  | 5.9 (3.3) | 8.7 (3.5) |  |
| **Lauren type** |  |  | 0.952 |  |  | 1 |
| Intestinal | 18 (40.9) | 10 (41.7) |  | 21 (41.2) | 7 (41.2) |  |
| Diffuse/mixed | 26 (59.1) | 14 (58.3) |  | 30 (58.8) | 10 (58.8) |  |
| **Grade of histological differentiation** | |  | 0.438 |  |  | 0.449 |
| Well/mod differentiated | 15 (34.1) | 6 (25) |  | 17 (33.3) | 4 (23.5) |  |
| Poorly differentiated | 29 (65.9) | 18 (75) |  | 34 (66.7) | 13 (76.5) |  |
| **Lymphatic invasion** |  |  | 0.176 |  |  | 1 |
| No | 14 (31.8) | 4 (16.7) |  | 14 (27.5) | 4 (23.5) |  |
| Yes | 30 (68.2) | 20 (83.3) |  | 37 (72.5) | 13 (76.5) |  |
| **Venous invasion** |  |  | **0.017** |  |  | 0.262 |
| No | 28 (63.6) | 8 (33.3) |  | 29 (56.9) | 7 (41.2) |  |
| Yes | 16 (36.4) | 16 (66.7) |  | 22 (43.1) | 10 (58.8) |  |
| **Perineural invasion** |  |  | 0.417 |  |  | 0.558 |
| No | 14 (31.8) | 10 (41.7) |  | 19 (37.3) | 5 (29.4) |  |
| Yes | 30 (68.2) | 14 (58.3) |  | 32 (62.7) | 12 (70.6) |  |
| **Peritumoral inflammatory response** | |  | **< 0.001** |  |  | **0.011** |
| Absent/mild | 32 (72.7) | 6 (25) |  | 33 (64.7) | 5 (29.4) |  |
| Moderate/severe | 12 (27.3) | 18 (75) |  | 18 (35.3) | 12 (70.6) |  |
| **pT status** |  |  | 0.734 |  |  | 0.268 |
| pT1/T2 | 8 (18.2) | 3 (12.5) |  | 10 (19.6) | 1 (5.9) |  |
| pT3/T4 | 36 (81.8) | 21 (87.5) |  | 41 (80.4) | 16 (94.1) |  |
| **No of lymph nodes** |  |  | 0.964 |  |  | **0.035** |
| mean (SD) | 42.3 (13.9) | 42.5 (19.4) |  | 40.1 (14.3) | 49.4 (18.7) |  |
| **No of positive lymph nodes** | |  | 0.961 |  |  | 0.486 |
| mean (SD) | 7 (6.4) | 6.9 (6.9) |  | 6.7 (6.1) | 7.9 (7.7) |  |
| **pN status** |  |  | 1 |  |  | 0.879 |
| pN1 | 9 (20.5) | 5 (20.8) |  | 11 (21.6) | 3 (17.6) |  |
| pN2 | 18 (43.2) | 11 (45.8) |  | 23 (45.1) | 7 (41.2) |  |
| pN3 | 16 (36.4) | 8 (33.3) |  | 17 (33.3) | 7 (41.2) |  |
| **pTNM status** |  |  | 1 |  |  | 0.299 |
| I/II | 9 (20.5) | 5 (20.8) |  | 12 (23.5) | 2 (11.8) |  |
| III/IV | 35 (79.5) | 19 (79.2) |  | 39 (76.5) | 15 (88.2) |  |

*P* values in bold are statistically significant. PD-L1: Programmed death-ligand 1.